-+ 0.00%
-+ 0.00%
-+ 0.00%
Sanofi Signs Up to $1.2 Billion Research, Exclusive License Deal with US-based Seawolf Therapeutics
Share
Listen to the news
05:39 AM EST, 11/16/2026 (MT Newswires) -- Sanofi (SAN.PA) signed a multi-target research collaboration and exclusive license agreement with US-based biotechnology company Seawolf Therapeutics. Under the deal, the partners will develop undisclosed therapies for bleeding disorders and additional unnamed indications, according to a Monday release. Up to $1.2 billion in milestones and tiered royalties on sales are expected.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending